Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

A daily dose of blarcamesine restored autophagy among patients with early Alzheimer’s disease, with improved outcomes through 192 weeks, according to an abstract presented at the Alzheimer’s ...

Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly su ...

ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; 12-week study results expected in Q4 2026Evenamide, a first-in-class glutamate ...

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks. The results ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This whitepaper will show leaders how strategic insights and targeted outreach can turn ...

Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase 2, causing the UK biotech’s shares to plunge.